Logo image of COV.PA

COVIVIO (COV.PA) Stock Fundamental Analysis

EPA:COV - Euronext Paris - Matif - FR0000064578 - REIT - Currency: EUR

52.8  +0.25 (+0.48%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to COV. COV was compared to 44 industry peers in the Diversified REITs industry. There are concerns on the financial health of COV while its profitability can be described as average. COV has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

COV had positive earnings in the past year.
COV had a positive operating cash flow in the past year.
Of the past 5 years COV 4 years were profitable.
COV had a positive operating cash flow in each of the past 5 years.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

COV's Return On Assets of 0.27% is on the low side compared to the rest of the industry. COV is outperformed by 63.64% of its industry peers.
The Return On Equity of COV (0.83%) is worse than 63.64% of its industry peers.
COV's Return On Invested Capital of 3.14% is in line compared to the rest of the industry. COV outperforms 45.45% of its industry peers.
The Average Return On Invested Capital over the past 3 years for COV is in line with the industry average of 3.64%.
The 3 year average ROIC (2.97%) for COV is below the current ROIC(3.14%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.27%
ROE 0.83%
ROIC 3.14%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

With a Profit Margin value of 5.23%, COV is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
In the last couple of years the Profit Margin of COV has declined.
Looking at the Operating Margin, with a value of 61.20%, COV is doing worse than 63.64% of the companies in the same industry.
COV's Operating Margin has been stable in the last couple of years.
COV's Gross Margin of 76.74% is fine compared to the rest of the industry. COV outperforms 61.36% of its industry peers.
In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 61.2%
PM (TTM) 5.23%
GM 76.74%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), COV is destroying value.
The number of shares outstanding for COV has been increased compared to 1 year ago.
Compared to 5 years ago, COV has more shares outstanding
COV has a better debt/assets ratio than last year.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

COV has an Altman-Z score of 0.56. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.56, COV is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
The Debt to FCF ratio of COV is 27.72, which is on the high side as it means it would take COV, 27.72 years of fcf income to pay off all of its debts.
COV has a worse Debt to FCF ratio (27.72) than 68.18% of its industry peers.
COV has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of COV (1.14) is worse than 79.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.72
Altman-Z 0.56
ROIC/WACC0.55
WACC5.69%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

COV has a Current Ratio of 0.96. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
COV has a Current ratio of 0.96. This is in the better half of the industry: COV outperforms 70.45% of its industry peers.
COV has a Quick Ratio of 0.96. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
COV has a better Quick ratio (0.85) than 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.85
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

COV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.00%.
The Earnings Per Share has been decreasing by -3.39% on average over the past years.
Looking at the last year, COV shows a very strong growth in Revenue. The Revenue has grown by 22.79%.
COV shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.17% yearly.
EPS 1Y (TTM)0%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%5.69%
Revenue 1Y (TTM)22.79%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.62%

3.2 Future

COV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.89% yearly.
The Revenue is expected to grow by 4.79% on average over the next years.
EPS Next Y7.5%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
EPS Next 5YN/A
Revenue Next Year-0.42%
Revenue Next 2Y1.71%
Revenue Next 3Y4.79%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 11.81, the valuation of COV can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of COV indicates a somewhat cheap valuation: COV is cheaper than 70.45% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.25, COV is valued rather cheaply.
COV is valuated reasonably with a Price/Forward Earnings ratio of 10.99.
COV's Price/Forward Earnings ratio is in line with the industry average.
COV is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.15, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 11.81
Fwd PE 10.99
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

COV's Enterprise Value to EBITDA ratio is in line with the industry average.
COV's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 15.32
EV/EBITDA 17.44
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

COV's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.58
PEG (5Y)N/A
EPS Next 2Y1.92%
EPS Next 3Y1.89%

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.99%, COV is a good candidate for dividend investing.
COV's Dividend Yield is a higher than the industry average which is at 6.80.
COV's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
Industry RankSector Rank
Dividend Yield 6.99%

5.2 History

The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years1
Div Non Decr Years1
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

COV pays out 112.19% of its income as dividend. This is not a sustainable payout ratio.
DP112.19%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COVIVIO

EPA:COV (5/30/2025, 7:00:00 PM)

52.8

+0.25 (+0.48%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)07-21 2025-07-21
Inst Owners40.89%
Inst Owner ChangeN/A
Ins Owners0.2%
Ins Owner ChangeN/A
Market Cap5.89B
Analysts80
Price Target60.78 (15.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.99%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP112.19%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.9%
PT rev (3m)-2.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)8.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.04%
Valuation
Industry RankSector Rank
PE 11.81
Fwd PE 10.99
P/S 4.53
P/FCF 15.32
P/OCF 6.01
P/B 0.72
P/tB 0.75
EV/EBITDA 17.44
EPS(TTM)4.47
EY8.47%
EPS(NY)4.81
Fwd EY9.1%
FCF(TTM)3.45
FCFY6.53%
OCF(TTM)8.78
OCFY16.64%
SpS11.66
BVpS73.72
TBVpS70.63
PEG (NY)1.58
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.27%
ROE 0.83%
ROCE 3.52%
ROIC 3.14%
ROICexc 3.24%
ROICexgc 3.29%
OM 61.2%
PM (TTM) 5.23%
GM 76.74%
FCFM 29.56%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
ROICexc(3y)3.08%
ROICexc(5y)2.79%
ROICexgc(3y)3.11%
ROICexgc(5y)2.81%
ROCE(3y)3.32%
ROCE(5y)3%
ROICexcg growth 3Y12.16%
ROICexcg growth 5Y0.31%
ROICexc growth 3Y11.77%
ROICexc growth 5Y0.14%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.72
Debt/EBITDA 10.32
Cap/Depr 519.44%
Cap/Sales 45.79%
Interest Coverage 250
Cash Conversion 107.61%
Profit Quality 564.76%
Current Ratio 0.96
Quick Ratio 0.85
Altman-Z 0.56
F-Score7
WACC5.69%
ROIC/WACC0.55
Cap/Depr(3y)709.28%
Cap/Depr(5y)708.5%
Cap/Sales(3y)50.08%
Cap/Sales(5y)56.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%5.69%
EPS Next Y7.5%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
EPS Next 5YN/A
Revenue 1Y (TTM)22.79%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.62%
Revenue Next Year-0.42%
Revenue Next 2Y1.71%
Revenue Next 3Y4.79%
Revenue Next 5YN/A
EBIT growth 1Y0.7%
EBIT growth 3Y7.42%
EBIT growth 5Y0.05%
EBIT Next Year11.8%
EBIT Next 3Y7.1%
EBIT Next 5YN/A
FCF growth 1Y-28.86%
FCF growth 3YN/A
FCF growth 5Y31.13%
OCF growth 1Y-4.37%
OCF growth 3Y12.5%
OCF growth 5Y4.86%